Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicentre, Double-blind, Prospective, Randomized, Placebo-controlled Study, Assessing the Efficacy and Safety of Dysport® Used for the Treatment of Lower-limb Spasticity in Adult Subjects With Hemiparesis Due to Stroke or Traumatic Brain Injury

NCT01249404 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT01249404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01249404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicentre, Double-blind, Prospective, Randomized, Placebo-controlled Study, Assessing the Efficacy and Safety of Dysport® Used for the Treatment of Lower-limb Spasticity in Adult Subjects With Hemiparesis Due to Stroke or Traumatic Brain Injury
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2011
Completion date
May 31, 2014
Enrollment
388 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

leg spasticity